460 likes | 734 Views
Limitations. Headache syndromes : Clinically diagnosed diseasesInhomogeneity Level I evidences are insufficient and limitedTreatment of acute migrainePrevention of migrainePrevention of tension headache. Chronic Headache. Very commonMigraineTension headacheCluster headacheOther rare headach
E N D
1. Evidence Based Guideline of Treatment of Chronic Headache Asan Medical Center
Sun U. Kwon
2. Limitations Headache syndromes : Clinically diagnosed diseases
Inhomogeneity
Level I evidences are insufficient and limited
Treatment of acute migraine
Prevention of migraine
Prevention of tension headache
3. Chronic Headache Very common
Migraine
Tension headache
Cluster headache
Other rare headache syndromes
Diagnosis is based on exclusion ? dilemma
Secondary headache
4. Contents Evaluation
Migraine
Acute treatment
Prevention
Treatment during pregnancy
Tension headache
prevention
5. Evaluation of Headache Using IHS Criteria
Indications for Neuroimaging
Focal neurological finding (Gr B)
Headache starting after exertion or valsalva’s maneuver
Acute onset of severe headache
Headaches awakens patient at night
Change in well-established headache pattern
New-onset headache in patient who has HIV or cancer (Gr C)
6. Treatment of Migraine
7. Treatment of Acute Attacks Analgesics and NSAIDs
Ergot Derivatives
Triptans
Opiates
8. NSAIDs First-line or initial choice for all migraine attacks
Followings have evidence for migraine
900mg aspirin, 1000mg acetaminophen(?), 500-1000mg naproxen, 400-800mg ibuprofen
Combination with antiemetic drugs or drugs for improving gastric motility
Overuse of these drugs should be avoided
9. Ergot Derivatives Ergotamine and dihydroergotamine (DHE)
Low cost and long experience
DHE : good evidence for the efficacy
Erogtamine or café-ergot : inconsistent evidence with frequent adverse events
Disadvantages
Sustained generalized vasoconstrictor
High risk of overuse and rebound
Complicated pharmacokinetics
10. Triptans Choice for moderate to severe migraine attacks
Advantages over ergotamine
Selective pharmacology: selective 5-HT1b/1d agonists
Established efficacy based on well-designed controlled trials
Well established safety profile
Moderate side effects
Disadvantages
High cost
Restrictions on their use in the presence of cardiovascular diseases
11. U.S. Headache Consortium Recommendations First-line : NSAIDs or acetaminophen+aspirin+caffeine
Use migraine specific agents in severe migraine or poor responder to NSAIDs
Triptans, DHE, ergotamine
Educate patients with migraine about their condition and its treatment
Guard against medication-overuse headache
12. AAFP/ACP-ASIM Recommendations First-line : NSAIDs
Fail to respond to NSAIDs
DHE nasal spray
Triptans
Educates patients with migraine about their condition and its treatment
13. Pharmacokinetics of Triptans
14. Fast Relief (Controlled Trials)